SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharmaceuticals informs about completion of USFDA inspection

26 Oct 2018 Evaluate

Alembic Pharmaceuticals has informed that the United States Food and Drug Administration (USFDA) has completed an inspection of its general oral solid formulation facility at Panelav, Gujarat, India. This was a scheduled pre-approval inspection carried out from 22nd October, 2018 to 26th October, 2018 and at the end of the inspection, the US FDA issued a Form 483 with four procedural observations. The Company will provide comprehensive corrective action report to address each observation. The Company is committed to maintaining highest quality standards that meet USFDA standards.

The above information is a part of company’s filings submitted to BSE.

Alembic Pharma Share Price

751.10 -18.70 (-2.43%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×